BiotechTubeBiotechTube
Home/Nuvalent/James Porter
JP

James Porter

Chief Executive Officer

Nuvalent

Therapeutic Areas

OncologyNon-Small Cell Lung CancerPrecision Medicine

Nuvalent Pipeline

DrugIndicationPhase
Zidesamtinib (NVL-520)TKI pre-treated advanced ROS1+ NSCLCPhase 2
Neladalkib (NVL-655)TKI pre-treated advanced ALK+ NSCLCPhase 2
NVL-330Advanced HER2-altered NSCLCPhase 1

Leadership Team at Nuvalent

AB
Alex Balcom
Chief Financial Officer
HP
Henry Pelish
Chief Scientific Officer
DN
Darlene Noci
Chief Development Officer
DM
Deb Miller
Chief Legal Officer
BL
Benjamin Lane
Chief Technical Operations Officer
RA
Ruth Adams
Senior Vice President, Clinical Operations
JH
Joshua Horan
Senior Vice President, Chemistry
JL
Jessie Lin
Senior Vice President, Corporate Strategy & Portfolio Management
MM
Matthew Metivier
Senior Vice President, Human Resources
SM
Steve Margossian
Clinical Development
View full Nuvalent profile